Rozanolixizumab May Safely Ease Symptom Severity in gMG Patients

Rozanolixizumab May Safely Ease Symptom Severity in gMG Patients

314173

Rozanolixizumab May Safely Ease Symptom Severity in gMG Patients

Rozanolixizumab, UCB’s investigational antibody, may ease symptom severity in adults with generalized myasthenia gravis (MG), and help them carry on with daily activities, top-line data from the Phase 3 MycarinG study suggests. Moreover, rozanolixizumab, given as an under-the-skin (subcutaneous) infusion, was found to be generally safe and well-tolerated. The company now plans to present final data from the study next year and to seek approval, in the third quarter of 2022, from regulatory authorities in…

You must be logged in to read/download the full post.